β-Blocker Use and Clinical Outcomes in Patients With COPD Following Acute Myocardial Infarction.

ABSTRACT:

Importance

While β-blockers are associated with decreased mortality in cardiovascular disease (CVD), exacerbation-prone patients with chronic obstructive pulmonary disease (COPD) who received metoprolol in the Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease (BLOCK-COPD) trial experienced increased risk of exacerbations requiring hospitalization. However, the study excluded individuals with established indications for the drug, raising questions about the overall risk and benefit in patients with COPD following acute myocardial infarction (AMI).

Objective

To investigate whether β-blocker prescription at hospital discharge is associated with increased risk of mortality or adverse cardiopulmonary outcomes in patients with COPD an

SUBMITTER: LaFon DC 

PROVIDER: S-EPMC11109775 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature